C5orf35 Inhibitors
C5orf35 Inhibitors exert their inhibitory effects through a variety of biochemical mechanisms that converge on the modulation of chromatin structure and gene expression. Some inhibitors achieve this by impeding the activity of enzymes responsible for adding acetyl groups to histones, a modification that is usually associated with active transcription. By preventing histone acetylation, these inhibitors can induce a more compact chromatin state, which is less accessible to the transcriptional machinery required for the expression of the C5orf35 gene. Other inhibitors operate by blocking the action of DNA methyltransferases, leading to changes in methylation patterns across the genome. Such changes can result in the demethylation of the C5orf35 gene promoter, which may allow the binding of transcriptional repressors and ultimately lead to decreased gene expression. In addition, certain inhibitors can interfere with the proteasome-mediated degradation pathway, leading to the accumulation of ubiquitinated proteins, which could indirectly affect the transcriptional regulation of the C5orf35 gene.
Further indirect mechanisms of C5orf35 inhibition involve the manipulation of cellular signaling pathways that govern gene expression. For instance, inhibitors that thwart the activation of transcription factors, such as those interfering with NF-kB signaling, have the potential to reduce the expression of C5orf35 if it is regulated by NF-kB-dependent pathways. Other inhibitors target the product of enzymatic reactions involved in methylation processes, which can alter histone and DNA methylation, potentially affecting the expression of C5orf35 by preventing the methylation-dependent transcriptional activation of the gene.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Histone deacetylase inhibitor that increases acetylation of histones, thereby altering chromatin structure and gene expression. This action can indirectly inhibit C5orf35 by promoting a chromatin state that is less conducive to the binding of transcription factors required for C5orf35 gene expression. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A DNA methyltransferase inhibitor that reduces DNA methylation, leading to the reactivation of silenced genes. It can decrease the expression of C5orf35 by demethylating its promoter region, which might lead to the binding of transcriptional repressors. | ||||||
Homocysteine | 6027-13-0 | sc-507315 | 250 mg | $195.00 | ||
As a product inhibitor of methyltransferases, it hinders the methylation of histones and DNA, potentially downregulating C5orf35 by preventing methylation-dependent transcriptional activation. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
A histone deacetylase inhibitor that promotes acetylation of histones, potentially decreasing C5orf35 expression by inducing a chromatin state that disfavors the binding of its specific transcriptional activators. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
A non-nucleoside DNA methyltransferase inhibitor that can lead to demethylation of the C5orf35 gene promoter, potentially allowing repressor proteins to bind and decrease C5orf35 expression. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
Selective histone deacetylase inhibitor that preferentially targets certain HDAC classes, potentially leading to reduced transcription of C5orf35 through histone modification changes. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $214.00 $247.00 $1463.00 | 2 | |
HDAC inhibitor that can alter gene expression by affecting acetylation patterns, possibly leading to a decrease in C5orf35 expression if it is regulated by acetylation-sensitive transcription factors. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
A hypomethylating agent that can cause DNA demethylation and reactivation of genes, potentially leading to reduced C5orf35 expression through the activation of methylation-sensitive repressive elements. | ||||||
Parthenolide | 20554-84-1 | sc-3523 sc-3523A | 50 mg 250 mg | $81.00 $306.00 | 32 | |
An inhibitor of NF-kB activation that may lead to decreased expression of C5orf35 if it is under the regulatory control of NF-kB dependent transcriptional pathways. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Proteasome inhibitor that can lead to the accumulation of ubiquitinated proteins, potentially decreasing C5orf35 expression indirectly by affecting the degradation pathways of transcription factors that activate the C5orf35 gene. | ||||||